Pluristem (PSTI) Stock
PSTI is no longer traded. Pluristem was delisted from the Nasdaq in September 2022.
Prices on this page are historical; the last trade was September 26, 2022 at $0.67.
Pluristem stock price history
PSTI final trading statistics
- Final close
- $0.67
- Final trading day
- Sep 26, 2022
- Market cap at delisting
- $21.67M
- Shares outstanding
- 32.35M
- Final 52-week range
- $0.66 – $3.19
- Avg. volume (final 3 mo.)
- 99,455
- All-time high (split-adj.)
- $36000.00 · May 2003
- All-time low (split-adj.)
- $5.36 · Sep 2022
- Return since IPO
- -99.7%
- Beta
- 1.91
- Book value / share
- $1.18
- Price / book
- 0.57
Pluristem annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $234.0K | -$41.2M | -$1.42 |
| FY2021 | $0.00 | -$49.9M | -$1.65 |
| FY2020 | $23.0K | -$29.2M | -$1.62 |
| FY2019 | $54.0K | -$35.3M | -$2.91 |
| FY2018 | $50.0K | -$26.1M | -$1.06 |
Last five fiscal years reported before the delisting; fiscal year ending June. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Pluristem
Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.
Pluristem stock FAQ
What happened to Pluristem stock?
Pluristem stock was delisted from the Nasdaq. Its final close was $0.67 on September 26, 2022.
Is PSTI stock still trading?
No. PSTI was delisted from the Nasdaq in September 2022 and no longer trades on a U.S. exchange.
What was the last price of PSTI stock?
PSTI closed at $0.67 on its final trading day, September 26, 2022, for a market value of about $21.67M.
What were Pluristem's revenue and earnings in its last full fiscal year?
Pluristem reported revenue of $234.0K and net income of -$41.2M in fiscal 2022, its last full year as a public company.
When did Pluristem go public?
Pluristem stock began trading on June 30, 2003.